Trexquant Investment LP Biotechnology

Trexquant Investment LP

$8.35 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
KYMR Kymera Therapeutics, Inc.	$2.53B	$2.21 Million 0.03% of portfolio	50,663	Q2 2025 New
RCUS Arcus Biosciences, Inc.	$830M	$2.11 Million 0.03% of portfolio	258,937	Q2 2025 Added 20.23%
SAGE Sage Therapeutics, Inc.	$516M	$2.03 Million 0.02% of portfolio	223,121	Q2 2025 Reduced 64.79%
VCYT Veracyte, Inc.	$2.28B	$2.02 Million 0.02% of portfolio	74,691	Q2 2025 Reduced 60.37%
ENTA Enanta Pharmaceuticals Inc	$179M	$2 Million 0.02% of portfolio	264,958	Q2 2025 Reduced 8.65%
PTGX Protagonist Therapeutics, Inc	$2.83B	$1.99 Million 0.02% of portfolio	36,018	Q2 2025 Reduced 65.36%
CNTA Centessa Pharmaceuticals PLC	$2.14B	$1.99 Million 0.02% of portfolio	151,352	Q2 2025 Reduced 42.67%
TBPH Theravance Biopharma, Inc.	$915M	$1.73 Million 0.02% of portfolio	156,930	Q2 2025 Reduced 5.13%
RPRX Royalty Pharma PLC	$16B	$1.71 Million 0.02% of portfolio	47,559	Q2 2025 New
MRUS Merus N.V.	$3.2B	$1.57 Million 0.02% of portfolio	29,857	Q2 2025 Reduced 52.14%
DNLI Denali Therapeutics Inc.	$1.99B	$1.53 Million 0.02% of portfolio	109,242	Q2 2025 Reduced 3.52%
XNCR Xencor Inc	$507M	$1.35 Million 0.02% of portfolio	171,420	Q2 2025 Added 28.54%
REPL Replimune Group, Inc.	$296M	$1.22 Million 0.01% of portfolio	131,485	Q2 2025 Reduced 13.8%
TGTX Tg Therapeutics, Inc.	$4.62B	$1.19 Million 0.01% of portfolio	33,195	Q2 2025 New
MDXG Mimedx Group, Inc.	$783M	$1.12 Million 0.01% of portfolio	183,815	Q2 2025 Reduced 55.69%
VIR Vir Biotechnology, Inc.	$694M	$1.1 Million 0.01% of portfolio	217,355	Q2 2025 New
TVTX Travere Therapeutics, Inc.	$1.6B	$1.07 Million 0.01% of portfolio	72,344	Q2 2025 Reduced 53.74%
CPRX Catalyst Pharmaceuticals, Inc.	$2.08B	$918,000 0.01% of portfolio	42,321	Q2 2025 Reduced 80.92%
CGEM Cullinan Oncology, Inc.	$295M	$898,000 0.01% of portfolio	119,342	Q2 2025 Added 74.31%
CDXC Chroma Dex Corp.	$420M	$822,000 0.01% of portfolio	133,887	Q2 2025 Reduced 36.18%
ARVN Arvinas, Inc.	$416M	$767,000 0.01% of portfolio	104,318	Q2 2025 New
DAWN Day One Biopharmaceuticals, Inc.	$541M	$750,000 0.01% of portfolio	115,427	Q2 2025 Reduced 43.63%
ABEO Abeona Therapeutics Inc.	$40M	$722,000 0.01% of portfolio	127,195	Q2 2025 Added 6.64%
IMCR Immunocore Holdings PLC	$1.61B	$605,000 0.01% of portfolio	19,289	Q2 2025 New
NRIX Nurix Therapeutics, Inc.	$422M	$586,000 0.01% of portfolio	51,533	Q2 2025 New
RYTM Rhythm Pharmaceuticals, Inc.	$5.46B	$447,000 0.01% of portfolio	7,083	Q2 2025 Reduced 81.71%
TYRA Tyra Biosciences, Inc.	$500M	$427,000 0.01% of portfolio	44,681	Q2 2025 New
CYTK Cytokinetics Inc	$5.02B	$359,000 0.0% of portfolio	10,894	Q2 2025 New
AKRO Akero Therapeutics, Inc.	$2.01B	$340,000 0.0% of portfolio	6,383	Q2 2025 New
TRVI Trevi Therapeutics, Inc.	$548M	$185,000 0.0% of portfolio	33,962	Q2 2025 New
KALV Kal Vista Pharmaceuticals, Inc.	$379M	$144,000 0.0% of portfolio	12,781	Q2 2025 New
TRDA Entrada Therapeutics, Inc.	$167M	$71,000 0.0% of portfolio	10,577	Q2 2025 Reduced 5.08%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.